There is much debate about the way in which epithelial tumors metastasize. It has been proposed that the bone marrow (BM) acts as a tumor cell reservoir. We injected human hepatocellular carcinoma (HCC) cells (Mahlavu cell line) into the livers, circulation or BM of NOD/SCID mice and circulating tumor cells were quantified. When injected under the Glisson capsule, a primary tumor developed and continuously yielded circulating tumor cells. Liver tumor removal led to a very low level of Mahlavu cells both in blood and BM 30 days later. When Mahlavu cells (cultured or from BM of primary mice femurs) were intravenously injected into mice, the number of cells in the bloodstream (BS) steadily decreased, whereas the BM was not significantly colonized. When Mahlavu cells were directly injected into one femur, the controlateral femur was not colonized. Microscopic analysis and a sensitive PCR assay (o1 Mahlavu cell/ nuclear cells) both failed to detect human tumor cells in other organs regardless of injection route. In conclusion, our model strongly supports the hypothesis that HCCs continuously release cells into the BS. However, in sharp contrast with the current hypothesis, the BM is not specifically colonized by tumor cells but could store them at a very low level.
Introduction
Hematogeneous dissemination is considered a major event in tumor progression, allowing early circulation from primary lesions and/or the circulation of tumor cells with newly acquired genetic alterations (Pantel and Brakenhoff, 2004) . Numerous studies have shown that the presence and number of circulating tumor cells influence both the probability of recurrence and the delay before recurrence in different tumor types (Braun et al., 2001; Guller et al., 2002; Gross-Goupil et al., 2003; Cristofanilli et al., 2004) . Gene profiling experiments suggested that primary tumors display genetic changes, indicating that metastasis could be an early event in tumorigenesis (Bernards and Weinberg, 2002; van't Veer et al., 2002; Ramaswamy et al., 2003) . The release and survival of tumor cells in the circulation can be considered efficient processes. Conversely, the ability of disseminating tumor cells to form metastasis is weak, uncertain and even delayed (Goodison et al., 2003) . Circulating cells may harbor the genetic diversity of the primary tumor but clonally selected cells may be expanded after dissemination has taken place leading to metastasis.
Solid tumors seem to exhibit different pathways of metastatic spreading (Gerber et al., 2001; Chambers et al., 2002; Osaki et al., 2002; Woelfle et al., 2003) . Disseminated tumor cells have been found in the bone marrow (BM) of patients with various types of solid tumors and mostly associated with a worse survival rate (Soeth et al., 1997; Braun et al., 2000 Braun et al., , 2001 ; Kienle et al., 2000; Gerber et al., 2001; Tsavellas et al., 2001; Solakoglu et al., 2002; Woelfle et al., 2003) , suggesting the implication of BM in tumor recurrence. Interestingly, the presence of disseminated tumor cells in the BM has been associated with the development of overt metastases in bone and in other organs (Lindemann et al., 1992; Pantel et al., 1996 Pantel et al., , 1999 Braun et al., 2001) . However, there is still much debate about whether the BM can act as a tumor cell reservoir, with or without additional or specific genetic changes, when the primary tumor has been completely removed.
The way in which primary liver tumors metastasize and relapse is still debated (Fukutomi et al., 2001; Li et al., 2004) . Liver cancers can be treated by orthotopic liver transplantation. Therefore, this can represent an accurate model to assess recurrences following the complete removal of the primary tumor and the surrounding tissue. Patients without tumoral extensions and with small hepatocellular carcinoma (HCC) tumors (size o3 cm, o3 nodes) according to Milan's consensus (Association for the Study of the Liver (AISF), 1992) can be transplanted. However, tumors recur in 20% of them within 2 years (Bismuth et al., 1993; Majno et al., 1997; Poon et al., 2002) . HCC tumor cells can infiltrate the BM and the blood system, as shown by the presence of alpha-fetoprotein (AFP) messenger RNA (mRNA) (Matsumura et al., 1994; Lemoine et al., 1997; Louha et al., 1999; Kienle et al., 2000; Gross-Goupil et al., 2003) . The number of circulating tumor cells has been related to tumor size (Matsumura et al., 1994; Lemoine et al., 1997; Minata et al., 2001; Gross-Goupil et al., 2003) and to the risk of recurrence (Minata et al., 2001; Qin and Tang, 2002; Gross-Goupil et al., 2003) . However, the relevance of AFP mRNA as a marker of circulating tumor cells is controversial because these cells have not been further characterized and because we and others have shown that they may correspond to normal circulating hepatocytes (Lemoine et al., 1997; Louha et al., 1999; Minata et al., 2001) . Furthermore, these tumor cells have mostly been sought and detected shortly after liver resection (Matsumura et al., 1994; Lemoine et al., 1997; Louha et al., 1999; Kienle et al., 2000; Minata et al., 2001) . Although the mechanisms leading to intra and extrahepatic recurrences are still unknown, some observations suggest that BM could be a specific reservoir. Indeed, several reports have suggested that tumor cells are of BM origin (Sell, 2002; Harris et al., 2004; Houghton et al., 2004; Marx, 2004) . Hepatic tumor stem cells may take advantage of the potential for stem cell support of the BM microenvironment.
The aim of this study was to develop a new experimental approach to detect and to characterize tumor cells in the bloodstream (BS), BM and other organs where hepatocarcinoma metastases tend to develop. To achieve this goal, we experimentally introduced human hepatic tumor cells into NOD-SCID mice. We used mice with normal livers to avoid the problem of cirrhosis, which is an advantage because cirrhotic tissue can be considered as a precancerous tissue making it difficult to distinguish between new tumors and metastases.
Results
Choice of cell line and cell detection method Invasive potential, in vitro, as well as tumorigenicity, in vivo, of three human hepatocellular carcinoma cell lines (HepG2, PLC/PRF/5 and Mahlavu) were initially tested. Tumoral cells with invasive potential, able to detach from primary tumors in mice livers and to invade subsequently into BS were needed for this study. For that purpose, invasive potential of the cell lines was assessed, in vitro, on transwells coated with matrigel. Mahlavu and PLC/PRF/5 were both found to be invasive in the used model, in vitro, whereas HepG2 was not found to be invasive (not shown, P. Riou personal data). Liver subcapsular injections of the cell lines, in vivo, showed that PLC/PRF/5 was the most tumorigenic, whereas Mahlavu cells had an intermediate growth capacity and HepG2 developed very small tumors even 2 months after injections (Figure 1 ). PLC/ PRF/5 cells were so tumorigenic that some animals already died 50 days after injections and other animals had big tumors which were not ethically acceptable. Therefore, PLC/PRF/5 cells were not chosen for that study. On the contrary, noninvasive HepG2 cells displayed a poor growth potential and few mice effectively developed tumors, and therefore, this cell line was not used also. In addition to its invasive potential, Mahlavu cells developed similar morphology to HCC affecting normal livers and was, therefore, used for this study.
These cells were detected by flow cytometry by combining the two light scatter parameters, forward (FSC) and side scatter (SSC), combined with immunofluorescent labeling using a human cell surface marker, HLA class I, (Figure 2 (Figure 2a and b) . These settings were well adapted for quantifying Mahlavu cells in mice blood since all cell types were contained within the R n region. On the other hand, these settings did not allow proper distinction of the whole BM cell population and Mahlavu cells thus preventing accurate relative quantification of Mahlavu cells in the BM. Therefore, for BM analysis, tumor cells were simply quoted as present or absent. Cells expressing HLA class I appeared in the R 2 window of the HLA class I/SSC plot. The ratio R 2 /R n was used to calculate the percent of tumor cells within the blood nucleated cells. Presence of HLA-positivity cells was not only assessed by the events count in R 2 but also by the distribution of these events. Indeed, as depicted in Figure 2b , significantly HLA-positive events yield a Tumor cells in the BM. We next used flow cytometry to detect Mahlavu cells in the BM (Figure 2c , lower panel). We confirmed that these tumor cells had a BM localization, beginning at D30, both by flow cytometry and human specific mtDNA measurements. To further Tumor cells in other organs. We also screened other tissues known to be typical sites of HCC metastases (e.g. lung, brain, bone, kidney and spleen) at D30 and D60 to identify if Mahlavu cells have colonized these organs after blood circulation. Both mtDNA detection allowing detection of at least 1 Mahlavu cell/per 10 6 nuclear cells and histological examination failed to detect tumor cells or secondary tumors in these organs.
Disappearance of circulating tumor cells after primary tumor removal. As the number of circulating tumor cells was correlated with the size of the initial tumor after intrahepatic tumor implantation, we evaluated the effect of tumor removal (partial hepatectomy on D30) on the number of detectable Mahlavu cells in the blood and the BM over time. Seven mice from the initial group of 26 mice underwent this operation. The number of detectable circulating cells at D60 were similar to the number of cells at D30 following tumor removal, whereas in sharp contrast mice without hepatectomy displayed a dramatic increase regarding the quantity of the latter (Figure 4 ). In the resected group, mtDNA measurements confirmed the presence of Mahlavu cells in the BM not only at D30 but also at D60, although FACS analysis failed to detect them. These results show that the primary tumor acts as a sustained source of exogenous tumor cells in the BS and, to a lesser extent, in the BM.
Intravenous tumor cell injection
Tail vein injection (TVI). We injected Mahalvu cells intravenously in order to analyse their outcome compared to tumor cells disseminating from a solid liver tumor. Mahlavu cells (10 5 ) were directly injected into the tail vein of 14 mice. Mice were killed, blood samples and BM samples were collected, respectively 7, 15, 30 or 45 days after injection. We assessed the distribution of Mahlavu cells in each compartment (Figure 5a ). Seven days after injection, Mahlavu cells were detected in the blood and in the BM. Mahlavu cells were detected in the BS in sustained quantities until the end of the experiment (D45). In contrast, cells in the BM were only detectable by mtDNA experiments at a very low level, but not by FACS analysis, at D30 and D45. These data confirm that, although Mahlavu cells seem to lack a specific homing ability towards the BM, they remain viable and thus detectable longer in the blood and the BM. (Table) . (a) Mahlavu cells were quantified in BS (each sample consisted of 200 ml of blood mouse) by flow cytometry at days 7, 15, 30, 45 and 60 after the initial tumor implantation. Total resection of the tumor was performed in one group (n ¼ 7) on day 30 (Hepatectomy þ ), whereas the other group (n ¼ 7) underwent a sham operation (laparotomy without hepatectomy: Hepatectomy -). (b) Mahlavu cells were quantified in BS (each sample consisted of 100 ml of whole blood mouse) by mtDNA PCR quantification at days 7, 15, 30, 45 and 60 after the initial tumor implantation. Three mice were killed on day 30 and BM from right was analysed by flow cytometry and BM from left femur was used to magnetic positive human cells selection and cultured in appropriate medium. Two mice were killed on D45 to the blood and BM kinetic cells.
The results of mtDNA PCR is expressed by the number of tumor cells per 10 6 nuclear cells present in blood or in BM. ND, not detectable; NT, not tested; n, number of mice.
Fate of circulating tumor cells of human liver cancer
O Scatton et al group of mice (n ¼ 8). This model differed from the TVI experiments in that the injected Mahlavu cells were not derived from a cultured cell line but from cells that had matured in vivo, in the liver. Significant numbers of Mahlavu cells could be detected in the BS, but not in corresponding marrow samples (Figure 5b ) at D15, D40 and D60. The kinetic profile obtained in these experiments is strikingly similar to that already observed in the TVI experiments. The observed decrease in the number of circulating tumor cells at later days cannot be due to preferential accumulation in the BM because all BM samples tested remained negative. We also studied two mice on the 120th day (data not shown); circulating cells were still detectable in both mice by flow cytometry and mtDNA analysis, whereas no cells were detected in the BM using both methods. Thus, our results confirm a lack of massive BM engraftment, indicating that Mahlavu cells cannot be specifically addressed to the BM, although BM or other organs could host tumoral cells at levels that could not be detected by our analytical methods.
Direct intra BM injection (IBMI) of Mahlavu cells
To further assess the ability of Mahlavu cells to colonize the BM and BS, we designed a model of intra-BM injection. Briefly, 100 000 Mahlavu cells were injected into the right femur of a cohort of 12 mice. We sought Mahlavu cells in the right (injected) and left femurs and in the BS 60 days after injection (Table 1) 
Discussion
We present a novel model for studying the generation of circulating cells by HCC. In contrast with current hypotheses (Sell, 2002; Harris et al., 2004; Houghton et al., 2004; Marx, 2004) , our results show that these circulating tumor cells do not necessarily home to the BM. Indeed, although we detected tumor cells in the BM during tumor growth and at low level 30 days after tumor removal from the liver, they did not preferentially accumulate in this compartment. According to our results, the BM appears to act as a passive filter interacting with the blood circulation, which explains why tumor cells were not specifically addressed to this tissue.
We injected primary human liver tumors directly into the livers of NOD/SCID mice under the Glisson capsule. The Mahlavu cell line was chosen on the basis of important criteria. First, these cells had appropriate tumorigenic properties in vivo, allowing the generation of tumors that were neither too aggressive nor quasiinactive. Second, the tumors generated by surgical implantation of these cells had similar pathological characteristics to the tumors found in clinical cases of HCC without underlying liver disease. This surgical implantation protocol avoided side effects linked to underlying chronic liver disease induced by chemical carcinogenesis (Ishikawa et al., 2004) . Hence, we were able to study the presence and kinetics of circulating cells both in the BS and the BM during the growth of a single liver tumor in a pure model of HCC development. Tumors generated in our model proved to be a source of circulating cells. The use of our method of cell quantification allowed a more precise quantification of circulating human tumor cells than that of AFP mRNA by RT-PCR (Liu et al., 2003) . Accordingly, we observed a significant positive correlation between initial tumor size (volume or area) and the number of tumor cells detected in the blood at any time as previously shown (Matsumura et al., 1994; Lemoine et al., 1997; Minata et al., 2001; Gross-Goupil et al., 2003) .
Our model of disseminated tumor cells was validated by the ex vivo culture of human cells isolated from BM. These cells were morphologically similar to Mahlavu cells and maintained their in vitro growth capabilities. To improve the detection of tumor cells that could not be detected histologically, we used a Taqman procedure to assess the human mitochondrial DNA content. This technique is more sensitive than the detection of nuclear genes because each cell can harbor 10-100 mitochondria and each mitochondrion can harbor 1-10 DNA copies. The oligonucleotides used were specific for the human genome and did not cross react with the mouse genome.
As the primary tumors developed rapidly and massively in the liver, the occurrence of distant metastases is not the major cause of death and could not constitute the end point of our study. However, the release of large numbers of circulating tumor cells by the primary tumors makes it possible to study the biological properties of these disseminating cells and their homing in the BM.
In sharp contrast with the situation in the BS, even though tumor cells could be detected in or even isolated from the BM, no correlation was found between tumor size and the quantity of tumor cells in the BM, suggesting the existence of a threshold of BM acceptance. This threshold of acceptance suggests that the BM actively and specifically eliminates tumor cells, by inducing apoptosis or phagocytosis for example. Alternatively, tumor cells could remain trapped in the BM vascular system and be unable to penetrate the stromal compartment. Additionally, the limited affinity of circulating tumor cells for the BM is emphasized by the observation that direct injection of Mahlavu cells into the tail vein did not result in stable colonization of the BM. To elucidate this point, we intravenously injected tumor cells that had already grown in the liver and migrated to the BM into 'secondary' mice. Again, no specific homing to the BM was observed. This model was thus a relevant way to investigate the occurrence of any mechanism of cellular instruction, either in the tumor or BM microenvironment, during tumor development. These data were corroborated by the finding that the injection of Mahlavu cells directly into the BM of one femur did not result in the invasion of the controlateral femur, although a tumor developed at the injection site.
Furthermore, removal of the primary tumors led to the detection of tumor cells both in the blood and BM samples at very low levels 30 days after surgery. This clearly indicates that these cells do not thrive in the BM and that no autonomous tumors develop from the cells arriving through the circulation. However, it is not the whole BM environment that is refractory to tumor development; a cellular defect could prevent them from reaching a site in the BM microenvironment where they can stay and proliferate. This is demonstrated by the finding that intrafemoral injection of tumor cells induced an invasive tumor, whereas tumor cells reaching the BM through the BS do not lead to the formation of intrafemoral tumors/metastases. Wounding and healing associated with IBMI could create the appropriate conditions for tumor development, for example, by triggering local angiogenesis and/or inflammation.
This experimental model also reveals that HCC cells injected intravenously or into the BM do not home to the liver. This was confirmed by the mtDNA PCR assay. This indicates that once cells have left this organ, they are unable to return to the site of origin of the tumor, at least in the first 2 months.
Finally, our results are in keeping with those reported in other cancers, especially colorectal or breast cancer (Braun et al., 2001; Guller et al., 2002; Gross-Goupil et al., 2003; Cristofanilli et al., 2004) , showing that circulating cells seem to be correlated with disease progression but not specifically implicated in tumor recurrence. A small number of studies found a correlation between the presence of tumor cells in the BM and metastatic relapse (Sell, 2002; Harris et al., 2004; Houghton et al., 2004; Marx, 2004) . A major pitfall of several studies was that they screened BM samples only before or during surgical tumor removal (Matsumura et al., 1994; Lemoine et al., 1997; Louha et al., 1999; Kienle et al., 2000; Minata et al., 2001) . The fact that BM was not examined during the follow-up meant it was not possible to assess the persistence of tumor cells in BM effectively.
This model highlights the importance of distinguishing tumor cell dissemination from metastasis. Metastasis appears to be a poorly efficient biological mechanism in which there is an enormous waste of disseminating tumor cells for a few that have the property to develop into a metastasis. The molecular events that endow tumor cells with a metastatic potential remain poorly understood. Profiling analyses have suggested that the metastatic potential may already be written in the genes of the primary tumor (Bernards and Weinberg, 2002; van't Veer et al., 2002; Ramaswamy et al., 2003; Weigelt et al., 2003) . This contradicts the previous hypothesis that metastatic cells are derived from primary tumor cells through the acquisition of further oncogenesis-related mutations. However, the results of profiling analyses failed to identify a mechanism that directly relates the genes that show expression variations ('metastatic signature') to metastatic potential. The disturbance of any network of molecular interactions leads to changes in gene expression that have only a small effect on the phenotype and does not necessarily point to the key genes involved in the process studied. The model of HCC developed in the liver of NOD/SCID mice could prove very useful for studying genes suspected to be central to metastatic properties. Nevertheless, our observations apply to a human cell line that can form tumors in NOD/SCID mice and results should be interpreted within the limits of the model. Since the experimental HCC that develops following Mahlavu cells intrahepatic injection has the ability to disseminate through the circulation but rarely to form metastasis within the 2-month-period of observation, it could be envisaged to select tumor cells that acquire this ability either through in vivo selection of cells that spontaneously form metastasis or after mutagenesis of the cell line. This would provide a tool for finding genes directly involved in the metastatic process.
In conclusion, our experiments demonstrate that circulating Mahlavu cells are not necessarily associated with distant metastasis. The in vitro adapted Mahlavu cell line is not genetically 'equipped' for colonization of distant organs when arriving through the circulation, even though it can disseminate in the blood and BM where it can remain at a very low level. Further studies on this animal model injected with genetically modified Mahlavu cells or tumor cells from patients could be useful to determine alterations predisposing HCC cells to colonize distant organs.
Materials and methods

Preparation of cells and culture
Mahlavu cells were subcultured weekly and grown at 371C in DMEM supplemented with 10% fetal calf serum, 10 U/ml penicillin and 10 mg/ml streptomycin. Cells obtained after BM flushing were purified by magnetic microbead cell sorting (MACS s technology, Miltenyi, Paris, France) using HLA-FITC antibody and anti-FITC-coated magnetic microbeads. Purified cells were cultured in the medium described above.
Experimental protocol
Mice Seven-to eight-week-old male NOD/SCID (Non Obese Diabetic/Severe Combined ImmunoDeficiency) mice were housed in microisolators, individually ventilated cages, and allowed sterilized water and food ad libitum. All experimental procedures were carried out according to European and French laws and regulations and internal biosafety and bioethics guidelines. Surgery and injections were practiced after general anesthesia with an intraperitoneal injection of Avertine s (Sigma, l'Isle D'Abeau France) and manipulated under sterile conditions. Mice were killed after general anesthesia by cervical dislocation.
Intrahepatic tumor injection: primary recipient mice Mice (n ¼ 26) were placed on a warm table under sterile conditions. An upper midline incision (1.5 cm. in length) was made to expose the xiphoid process. The left lower hepatic lobe was dissected, exposing its vascular pedicle. To avoid vascular diffusion of tumor cells, a 'tourniquet' system can be used to clamp the pedicle during subcapsular injection. In this case, the clamp is removed 5 min after injection. Based on our first results (data not shown), we decided to administer a single injection without clamping for two reasons: (1) the presence of necrotic lobes in some mice and (2) the lack of real advantage regarding accidental cell diffusion. Five million purified Mahlavu cells were injected into the left lower lobe under the Glisson capsule. The peritoneum was sealed with a running suture (5-0 vicryl, Ethicon s , Johnson-Johnson Intl., SaintStevens-Woluwe, Belgium) and the skin was stitched with a running 4-0 nylon suture. Blood samples were collected on days 0.5, 1, 3, 7, 15, 30 and 60 after injection. Mice were killed after general anesthesia on day 15, 30, 45 or 60.
Tumor removal by left lower lobectomy Tumors were removed surgically (70% hepatectomy) as described by Greene (Greene and Puder, 2003) . Briefly, after opening the abdomen under anesthesia, a retractor was inserted. The falciform ligament was divided. A 5-0 suture tie was placed underneath the left lower lobe in which the tumor had been implanted. The suture was positioned as proximal as possible to the origin of the lobe. The two ends of the suture were then tied near the vena cava. The mice were stitched back as previously described. This technique was carried out 30 days after tumor implantation in seven mice from the group of 26 mice. A simple laparotomy without tumor removal was performed in Tail vein injection (TVI) Under general anesthesia, 500 ml of PBS (1X) containing 100 000 purified Mahlavu cells was injected through the tail vein (n ¼ 14). Blood was taken 7, 15, 30 and 45 days following injection. The mice were killed 7, 15, 30 and 45 days after injection and bones (left and right femurs) were removed to search for tumor cells. Two mice died (on the 7th and 15th days) but bones were nonetheless removed.
Secondary mice The BM tissue of primary mice (n ¼ 8) was removed on day 30 after injection and injected into the tails of 'secondary mice' (n ¼ 8). The eight secondary mice were not irradiated. Briefly, after carefully removing all muscle from the bone, femoral heads were cutoff and marrow was collected using a 0.4 mm needle mounted on a 1 ml syringe filled with PBS. After gently inserting the needle into the femoral neck, the cells residing in the bone were expelled by vigorously flushing with the contents of the syringe. Pairs of femurs from the primary mice were flushed with a-medium containing 10% FCS. After cytometric screening to confirm the presence of Mahlavu cells, these BM cells were washed and resuspended in respectively 10 ml and 500 ml of 1 Â PBS buffer. The mice were then injected with the suspended cells via the tail vein.
Intra BM injection IBMI (n ¼ 12 mice) was carried out under general anesthesia and local anesthesia of the periosteum (Kushida et al., 2001; Esumi et al., 2003) . A lateral incision was made in the lower part of the femur and the knee was flexed to a 901 angle. A 27-gauge needle was then inserted into the femoral BM cavity and 100 000 purified Mahlavu cells were injected. The knee joint was preserved. Muscle and skin were closed with a suture. All mice were injected into the right femur, allowing a control with the controlateral (left) femur. All mice resumed normal mobility immediately after the surgical procedure. Mice were killed 60 days after IBMI.
Analysis of tumor cell engraftment
Flow cytometry analysis and settings Fluorescent-antibody labeling of whole blood and BM samples: Prior to antibody labeling, ammonium chloride solution (Sigma, l'Isle D'Abeau Chesnes, France) was added to blood samples to lyse erythrocytes according to the manufacturer's protocol. Remaining cells were then collected by centrifugation for 10 min at 1200 r.p.m., washed once in PBS containing 0.5% bovine serum albumin (BSA) and recentrifuged. Cell pellets were resuspended in 100 ml of PBS þ 0.5% BSA containing a specific FITC-conjugated anti-HLA antibody (clone B9.12.1, 2 mg/ml; Immunotech, Marseille, France) for 15-30 min in the dark at 41C. Optimal antibody concentrations were previously determined using the Mahlavu hepatocarcinoma cell line. After incubation, cells were washed twice in PBS þ 0.5% BSA and immediately submitted to flow cytometry analysis (FACS).
Histology Tissues and organs (liver, tumor, lung, kidney, spleen, femur and brain) were fixed in 10% neutral buffered formaldehyde and then embedded in paraffin. Sections (4-5 mm) were deparaffinized in xylene, rehydrated with ethanol, and rinsed in PBS. The sections were stained with hematoxylin and eosin to assess morphology.
DNA extraction and real-time mtDNA quantification Total DNA was extracted from various biological samples (e.g. liver, blood, BM) using ATL buffer supplemented with proteinase K (10 mg/ml) and then purified using a QiaAmp-DNA mini Kit (Qiagen s , Courtaboeuf, France) according to the manufacturer's instructions.
Mahlavu cells (1 million to start) were diluted several times (10-fold) in whole blood (100 ml in each dilution) to obtain a standard curve and positive threshold for the determination of the sensitivity of the method. Total DNA was extracted from whole blood with and without Mahlavu cells dilution, the last as negative control and the QiaAmp DNA mini kit (Qiagen, Courtaboeuf, France) was used. The total DNA obtained was used as a reference to determine whether Mahlavu cells were present in the different tissues. DNA was kept at À801C and mitochondrial DNA (mtDNA) was quantified as previously described (Chiappini et al., 2004) . Briefly, we amplified a part of the cyt b mitochondrial gene by use of specific primers, Mito-CytB-F CAACATCTCCGCATGATGAAA and MitoCytB-R CCATAATTTACGTCTCGAGTGATGTG and a specific probe 5 0 -6-Fam-CCATGCACTACTCACCAGACG CCTCAA-3 0 -Tamra. The b-actin gene was amplified by the Taqman b-Actin s mix (Roche, France). The PCR mixtures contained 7 ml of water, 12.5 ml of QPCRmastermix s (Eurogentec, France), 0.4 pmol/ml of each primer and 0.2 pmol/ml of each probe. Each sample was subjected to real-time PCRs in triplicate. The amplification conditions consisted of an enzyme activation of 2 min at 501C, followed by a single denaturation step of 10 min at 951C, and 50 cycles of 15 s at 951C and 1 min at 601C. Fluorescence was measured at the end of each annealing step. The mtDNA content of tissues was determined by comparison with the standard curve serial dilution of Mahlavu cells DNA in mouse whole blood or BM. The method allows the detection of at least 1 Mahlavu cell per 10 6 nuclear cells from mouse whole blood or BM.
